Dasatinib, a Src inhibitor, was feasible as neoadjuvant therapy for bladder cancer.
Overall, significant Src pathway inhibition was seen in tumor tissue.
Cell proliferation and apoptosis were unaltered overall.
Src inhibition appears ineffective in unselected bladder cancer patients.
The neoadjuvant trial paradigm may complement drug development.